Eisai Acquires Elan's Zonegran; Will Detail With Aricept
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.
You may also be interested in...
Japanese Biotechs Promote "Relationship Building" In Developing Marketing Deals
Building solid relationships with licensing partners is key to sustaining and expanding those alliances in the long term, Eisai VP-Business Development Alex Scott said during a May 8 panel discussion at the Biotechnology Industry Organization International Convention in Boston
Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals
Eisai and Astellas execs tell BIO attendees that forming strong initial partnerships provides a basis for expanding alliances into new products and geographies.
Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals
Eisai and Astellas execs tell BIO attendees that forming strong initial partnerships provides a basis for expanding alliances into new products and geographies.